Fennec Pharmaceuticals Inc. (FENC) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

and only mode. Later, we will conduct a question and answer session, and instructions on how to participate will be given at that time. As a reminder, today's conference call is being recorded. Now, I would like to turn the conference over to Phenix Chief Financial Officer Robert Andrade. Thank you, Operator, and good morning, everyone. We appreciate you joining us today for Phenix Pharmaceutical's first quarter of 2025 Earnings Conference Call, during which we will review our financial results as well as provide a general business update. Joining me from FENIC this morning is our Chief Executive Officer and Board Member, Jeff Hackman. Before we begin, I would like to remind you that during this call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ. from the results discussed in the forward-looking statements. Reference to these risks and uncertainties are made in today's press release and disclosed in detail in the company's periodic and current event filings with the U.S. Securities and Exchange Commission. In addition, any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. This conference call is being recorded for audio rebroadcast on Fennec's website, www.fennecpharma.com, where it will be available for the next 30 days. And with that, I will now turn the call over to Jeff Hackman. Thank you, Robert. And good morning, everyone. Wanted to thank you all for joining us today as we review our first quarter performance and share the outlook for the year ahead. I'm excited to s...